Format

Send to:

Choose Destination
See comment in PubMed Commons below
Future Microbiol. 2011 Oct;6(10):1185-98. doi: 10.2217/fmb.11.101.

Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?

Author information

  • 1Johns Hopkins University Center for Tuberculosis Research, 1551 Jefferson Street, #154, Baltimore, MD 21287, USA. pconver1@jhmi.edu

Abstract

Until 2004, the skin disease known as Buruli ulcer, caused by Mycobacterium ulcerans, could only be treated by surgery and skin grafting. Although this worked reasonably well on early lesions typically found in patients in Australia, the strategy was usually impractical on large lesions resulting from diagnostic delay in patients in rural West Africa. Based on promising preclinical studies, treatment trials in West Africa have shown that a combination of rifampin and streptomycin administered daily for 8 weeks can kill M. ulcerans bacilli, arrest the disease, and promote healing without relapse or reduce the extent of surgical excision. Improved treatment options are the focus of research that has increased tremendously since the WHO began its Global Buruli Ulcer Initiative in 1998.

PMID:
22004037
[PubMed - indexed for MEDLINE]
PMCID:
PMC3243445
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Write to the Help Desk